263 related articles for article (PubMed ID: 37213280)
1. Liquid biopsies and minimal residual disease in myeloid malignancies.
Allam S; Nasr K; Khalid F; Shah Z; Khan Suheb MZ; Mulla S; Vikash S; Bou Zerdan M; Anwer F; Chaulagain CP
Front Oncol; 2023; 13():1164017. PubMed ID: 37213280
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
Shapiro RM; Kim DDH
Curr Opin Hematol; 2018 Nov; 25(6):425-432. PubMed ID: 30281033
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsies and minimal residual disease in lymphoid malignancies.
Bou Zerdan M; Kassab J; Saba L; Haroun E; Bou Zerdan M; Allam S; Nasr L; Macaron W; Mammadli M; Abou Moussa S; Chaulagain CP
Front Oncol; 2023; 13():1173701. PubMed ID: 37228488
[TBL] [Abstract][Full Text] [Related]
4. The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies.
Colmenares R; Álvarez N; Barrio S; Martínez-López J; Ayala R
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267616
[TBL] [Abstract][Full Text] [Related]
5. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
6. Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome.
Ko BS; Wang YF; Li JL; Li CC; Weng PF; Hsu SC; Hou HA; Huang HH; Yao M; Lin CT; Liu JH; Tsai CH; Huang TC; Wu SJ; Huang SY; Chou WC; Tien HF; Lee CC; Tang JL
EBioMedicine; 2018 Nov; 37():91-100. PubMed ID: 30361063
[TBL] [Abstract][Full Text] [Related]
7. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
8. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method.
Hoffmann J; Thrun MC; Röhnert MA; von Bonin M; Oelschlägel U; Neubauer A; Ultsch A; Brendel C
Cytometry A; 2023 Apr; 103(4):304-312. PubMed ID: 36030398
[TBL] [Abstract][Full Text] [Related]
9. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Xiao W; Petrova-Drus K; Roshal M
Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
[TBL] [Abstract][Full Text] [Related]
10. Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia.
Vial JP; Lechevalier N; Lacombe F; Dumas PY; Bidet A; Leguay T; Vergez F; Pigneux A; Béné MC
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562525
[TBL] [Abstract][Full Text] [Related]
11. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
12. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
13. Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry.
Li W; Morgan R; Nieder R; Truong S; Habeebu SSM; Ahmed AA
Cytometry B Clin Cytom; 2021 Sep; 100(5):590-601. PubMed ID: 33197125
[TBL] [Abstract][Full Text] [Related]
14. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.
Wood BL
Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834
[TBL] [Abstract][Full Text] [Related]
15. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.
Brar N; Lawrence L; Fung E; Zehnder JL; Greenberg PL; Mannis GN; Zhang TY; Gratzinger D; Oak J; Silva O; Kurzer J; Tan B; Menke JR; Fernandez-Pol S
Am J Clin Pathol; 2024 Apr; ():. PubMed ID: 38643353
[TBL] [Abstract][Full Text] [Related]
16. Role of Biomarkers in the Management of Acute Myeloid Leukemia.
Small S; Oh TS; Platanias LC
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498870
[TBL] [Abstract][Full Text] [Related]
17. Status of minimal residual disease testing in childhood haematological malignancies.
Campana D
Br J Haematol; 2008 Nov; 143(4):481-9. PubMed ID: 18710378
[TBL] [Abstract][Full Text] [Related]
18. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.
Tomlinson B; Lazarus HM
Expert Rev Hematol; 2017 Jun; 10(6):563-574. PubMed ID: 28475434
[TBL] [Abstract][Full Text] [Related]
19. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges.
Riva G; Nasillo V; Ottomano AM; Bergonzini G; Paolini A; Forghieri F; Lusenti B; Barozzi P; Lagreca I; Fiorcari S; Martinelli S; Maffei R; Marasca R; Potenza L; Comoli P; Manfredini R; Tagliafico E; Trenti T; Luppi M
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
